Prospective evaluation of patients' preferences of three different regimens in a phase II study of FU, oxaliplatin, mitomycin C and CPT-11 in advanced colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3757-3757
Author(s):  
A. Guglielmi ◽  
M. Cirillo ◽  
S. Mammoliti ◽  
G. Fornarini ◽  
C. Caroti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Prospective Evaluation

Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer

2003 ◽  
Vol 52 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Tadamichi Denda ◽  
Tomonori Ambo ◽  
Atsushi Ohtsu ◽  
Yasuhide Yamada ◽  
Kuniaki Shirao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Combination Therapy ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study

Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study

2012 ◽  
Vol 24 (4) ◽  
pp. 207-211 ◽  
Author(s):  
Eric Francois ◽  
Denis Smith ◽  
Laetitia Dahan ◽  
Cecile Michel ◽  
Hervé Perrier ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Salvage Therapy ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study

The Combination of Raltitrexed (Tomudex) and Mitomycin-C in the Treatment of Advanced Colorectal Cancer — A Phase II Study

2006 ◽  
Vol 18 (6) ◽  
pp. 431-435 ◽  
Author(s):  
J. Michels ◽  
T. Geldart ◽  
A. Darby ◽  
L. Craddock ◽  
A. Iveson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

2005 ◽  
Vol 56 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Do Hyoung Lim ◽  
Young Suk Park ◽  
Byeong-Bae Park ◽  
Sang Hoon Ji ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer

2011 ◽  
Vol 2 (6) ◽  
pp. 1253-1256 ◽  
Author(s):  
JUNG HAN KIM ◽  
HYEONG SU KIM ◽  
DAE RO CHOI ◽  
GEUNDOO JANG ◽  
JUNG HYE KWON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer

2000 ◽  
Vol 82 (11) ◽  
pp. 1776-1782 ◽  
Author(s):  
D J Propper ◽  
N C Levitt ◽  
K O’Byrne ◽  
J P Braybrooke ◽  
D C Talbot ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Oxygen Saturation ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Saturation Curve

Mitomycin-C and Lonidamine as Second-Line Therapy for Colorectal Cancer: A Phase II Study

1995 ◽  
Vol 81 (6) ◽  
pp. 435-437 ◽  
Author(s):  
Alberto Zaniboni ◽  
Fausto Meriggi ◽  
Alberto Alghisi ◽  
Stefano Mutti ◽  
Luciana Distefano ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Anticancer Agents ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Objective Response ◽  
Human Colon ◽  
Hematologic Toxicity ◽  
Human Colon Cancer

Aims and background Recent preclinical data have suggested that lonidamine may potentiate the activity of mitomycin C in human colon cancer cell lines LoVo and HT29. Study design A phase II study was carried out in 14 patients with advanced colorectal cancer pretreated with fluorouracil and folinic acid. Treatment consisted of lonidamine, 600 mg po, followed after 2 h by mitomycin, 20 mg/m2 by iv bolus, followed by lonidamine, 150 mg tid for 5 days; the cycle was repeated every 6 weeks. Results No objective response was seen. Three patients had stable disease; the median survival for the whole group was 4 months. Although hematologic toxicity was negligible, lonidamine-related side effects were moderate to severe in most patients and mainly represented by myalgia and gastric pain. Discussion Despite a sound preclinical rationale, this schedule of lonidamine and mitomycin C was ineffective and toxic in patients with advanced colorectal cancer. More experimental data about lonidamine are needed in order to design more effective regimens based on the combination of this interesting drug with other anticancer agents.

scholarly journals Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

2004 ◽  
Vol 91 (5) ◽  
pp. 839-843 ◽  
Author(s):  
S Rao ◽  
D Cunningham ◽  
T Price ◽  
M E Hill ◽  
P J Ross ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document